Fig. 1: Pancancer analysis of tumor-infiltrating T cells reveals that the mitochondrial metabolic gene SARDH is related to CD8⁺ T-cell dysfunction.

A Bar plot illustrating the number of significantly dysregulated pathways across each cancer type. B Heatmap illustrating the scaled pathway score and the number of significantly dysregulated pathways across each cancer type. C Scheme of the computational analysis workflow for screening candidate mitochondrial metabolic genes. D Three-dimensional plot showing all mitochondria-related genes with enrichment scores, exhaustion scores, and numbers of cancer types in which genes were significantly upregulated in exhausted T cells. E Bar plot showing the number of mitochondria-related genes significantly upregulated in exhausted T cells among different numbers of cancer types. F Scatterplot showing that the enrichment score and exhaustion score of mitochondria-related genes were significantly increased in all 18 collected cancer types. G UMAP plot showing SARDH expression in CD8⁺ T cells. H Bar plot showing log₂ (fold change) values of SARDH in exhausted T cells across each cancer type. I Enzymatic reaction of sarcosine decomposition catalyzed by SARDH. The cancer type abbreviations used are as follows: BCC basal cell carcinoma, BC breast cancer, BCL B-cell lymphoma, CHOL cholangiocarcinoma, CRC colorectal cancer, ESCA esophageal carcinoma, HCC hepatocellular carcinoma, LC lung cancer, MELA melanoma, MM multiple myeloma, NPC nasopharyngeal cancer, OV ovarian cancer, PACA pancreatic cancer, RC renal carcinoma, SCC squamous cell carcinoma, STAD stomach adenocarcinoma, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma